ERIS Lifesciences Ltd Share Price (ERIS)
₹875.1▲0.55%
ERIS Lifesciences Ltd share Performance
- ₹855₹879.9₹875.1
2.30%
Low
Day's Volatility:2.85%
High
0.55%
- ₹602₹971.9₹875.1
31.21%
Low
52 Weeks Volatility:42.27%
High
11.06%
| Returns % | |
| 1 Month Return | 2.72 % |
| 3 Month Return | -2.35 % |
| 1 Year Return | 40.47 % |
| Market Stats | |
| Previous Close | ₹870.30 |
| Open | ₹860.00 |
| Volume | 1.49L |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹11,840.21Cr |
Analyst Rating for ERIS Lifesciences Ltd stock
based on 8 analysts
Based on 8 analysts offering long term price targets for ERIS Lifesciences Ltd. An average target of ₹1080.62
Source: S&P Global Market Intelligence
Company Information
Share Price: ₹875.10 per share as on 19 Apr, 2024 04:01 PM
Market Capitalisation: ₹11,840.21Cr as of today
Revenue: ₹483.48Cr as on December 2023 (Q4 23)
Net Profit: ₹101.46Cr as on December 2023 (Q4 23)
Listing date: 29 Jun, 2017
Chairperson Name: Amit Indubhushan Bakshi
| Organisation | ERIS Lifesciences Ltd |
| Headquarters | Ahmedabad |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for ERIS Lifesciences Ltd
Prabhudas Lilladher Rates Eris Lifesciences as BUY - 09 Apr, 2024
Prabhudas Lilladher has given a BUY rating to Eris Lifesciences with a target of Rs 1,100. The company is expected to benefit from patent expirations in the cardiometabolic market and operating leverage as revenue scales up from acquisitions.
ERIS Lifesciences to Acquire Biocon Biologics' India Branded Formulation Business - 18 Mar, 2024
ERIS Lifesciences has agreed to acquire the India branded formulation business of Biocon Biologics for INR12.4b, expanding its presence in the domestic injectable market in diabetes and oncology areas. The deal is valued at 12x 1-year forward EV/EBITDA, implying 25% YoY growth in EBITDA after the acquisition. ERIS also proposed to buy a 19% stake in Swiss Parenterals from ERIS promoters for INR2.4b.
Eris Lifesciences Enters Indian Injectables Market with Acquisition of Biocon Business - 15 Mar, 2024
Eris Lifesciences is set to enter the Indian injectables market with the acquisition of Biocon Biologics India's branded formulation business for Rs 1,242 crore. The deal brings two major insulin brands under Eris and marks its entry into oncology and critical care.
Eris Lifesciences Acquires Biocon's Branded Formulations Business - 14 Mar, 2024
Eris Lifesciences has acquired Biocon Biologics' Branded Formulations business in India for Rs 1,242 crore, giving it a leadership position in the insulin division and putting it in the oncology and critical care industries. The acquisition brings two leading insulin products under Eris's umbrella, propelling its diabetes care unit to potentially earn Rs 1,000 crore in revenue.
HDFC Securities Recommends Buy on Eris Lifesciences with Target Price of Rs 1070 - 13 Mar, 2024
Eris Lifesciences Ltd. is a mid-cap pharmaceutical company with a market cap of Rs 11,707.95 crore. HDFC Securities has recommended a buy call on the stock with a target price of Rs 1070, citing strong financials and growth prospects.
Fundamentals of ERIS Lifesciences Ltd
Insights on ERIS Lifesciences Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRetail Holding Up
Retail Investor have increased holdings from 17.37% to 17.41% in Dec 2023 quarter
- POSITIVE IMPACT
Price Rise
In the last 7 days, ERIS stock has moved up by 2.7%
NO EFFECTAgainst Peers
In the last 3 years, Sun Pharmaceuticals Industries Ltd has given 136.7% return, outperforming this stock by 86.8%
- NO EFFECT
Against Peers
In the last 1 year, Sun Pharmaceuticals Industries Ltd has given 52.3% return, outperforming this stock by 11.9%
NEGATIVE IMPACTRevenue Fall
Revenue is down for the last 2 quarters, 508.78 Cr → 490.49 Cr (in ₹), with an average decrease of 3.6% per quarter
- NEGATIVE IMPACT
Promoter Holding Down
Promoters have decreased holdings from 54.91% to 54.90% in Dec 2023 quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 13.20% to 13.14% in Dec 2023 quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 123.43 Cr → 102.74 Cr (in ₹), with an average decrease of 16.8% per quarter
- NEGATIVE IMPACT
MF Holding Down
Mutual Funds have decreased holdings from 13.86% to 13.85% in Dec 2023 quarter
ERIS Lifesciences Ltd Valuation
ERIS Lifesciences Ltd in the last 5 years
Lowest (16.77x)
September 9, 2019
Today (30.63x)
April 18, 2024
Industry (61.24x)
April 18, 2024
Highest (39.79x)
March 13, 2018
Mutual Fund Holdings
| Funds | Holdings |
 HDFC Small Cap Fund-Direct Growth Option | 1.69% |
 UTI Flexi Cap Fund - Growth Option - Direct | 0.78% |
| HDFC Hybrid Equity Fund Direct Growth Option | 0.69% |
 Franklin India Smaller Companies Fund Direct Growth | 1.25% |
| UTI Value fund Fund-Direct Growth Option | 1.01% |
Shareholding Pattern
| Investors | Holdings % | Prev. 4 periods | 3M change |
|---|---|---|---|
| Promoter Holdings | 54.9% | 0.00 | |
| Foreign Institutions | 13.14% | ||
| Mutual Funds | 13.85% | ||
| Retail Investors | 17.41% | 0.21 | |
| Others | 0.7% | 5.95 |
Technicals of ERIS Lifesciences Ltd share
News & Events of ERIS Lifesciences Ltd
Frequently Asked Questions
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy ERIS Lifesciences Ltd shares.
ERIS Lifesciences Ltd (ERIS) share price today is ₹875.1
ERIS Lifesciences Ltd is listed on NSE
ERIS Lifesciences Ltd is listed on BSE
- Today’s highest price of ERIS Lifesciences Ltd is ₹879.9.
- Today’s lowest price of ERIS Lifesciences Ltd is ₹855.
PE Ratio of ERIS Lifesciences Ltd is 30.63
PE ratio = ERIS Lifesciences Ltd Market price per share / ERIS Lifesciences Ltd Earnings per share
Today’s traded volume of ERIS Lifesciences Ltd(ERIS) is 1.49L.
Today’s market capitalisation of ERIS Lifesciences Ltd(ERIS) is ₹11840.21Cr.
| ERIS Lifesciences Ltd(ERIS | Price |
|---|---|
52 Week High | ₹971.9 |
52 Week Low | ₹602 |
ERIS Lifesciences Ltd(ERIS) share price is ₹875.1. It is down -9.96% from its 52 Week High price of ₹971.9
ERIS Lifesciences Ltd(ERIS) share price is ₹875.1. It is up 45.37% from its 52 Week Low price of ₹602
| ERIS Lifesciences Ltd(ERIS | Returns |
|---|---|
1 Day Returns | 4.8% |
1 Month Returns | 2.72% |
3 Month Returns | -2.35% |
1 Year Returns | 40.47% |